WO2024062236A1 - Combinaisons antimicrobiennes - Google Patents

Combinaisons antimicrobiennes Download PDF

Info

Publication number
WO2024062236A1
WO2024062236A1 PCT/GB2023/052429 GB2023052429W WO2024062236A1 WO 2024062236 A1 WO2024062236 A1 WO 2024062236A1 GB 2023052429 W GB2023052429 W GB 2023052429W WO 2024062236 A1 WO2024062236 A1 WO 2024062236A1
Authority
WO
WIPO (PCT)
Prior art keywords
concentration
doxycycline
ceftazidime
combination
polymyxin
Prior art date
Application number
PCT/GB2023/052429
Other languages
English (en)
Inventor
Robert J H HAMMOND
Anthony Coates
Yanmin Hu
Original Assignee
Helperby Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helperby Therapeutics Limited filed Critical Helperby Therapeutics Limited
Publication of WO2024062236A1 publication Critical patent/WO2024062236A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to a combination of at least four antimicrobial agents selected from rifampicin, levofloxacin, polymyxin E, polymyxin B, doxycycline, ceftazidime, and pharmaceutically acceptable derivatives thereof.
  • the present invention relates to the use of such combinations to kill multiplying (i.e. log phase) microorganisms associated with bacterial infections, e.g. Gram-negative bacterial infections.
  • NCEs new chemical entities
  • Each NCE requires more than 10 years’ development and costs in excess of $600 million to complete the necessary safety and clinical testing.
  • Substantial numbers fail and hence about $3.8 billion is typically required to deliver one NCE antibiotic.
  • antimicrobial resistance also develops faster as the antibiotic use increases meaning that all NCEs have a limited useful life, often less than 10 years.
  • Replacing the currently used antibiotics with NCEs would thus require approximately $3,800 billion within a 10 year period and if successful, these products would then require continued plans to replace them within their 10 year life as antimicrobial resistance develops to each one. This is clearly unsustainable, even for higher income countries.
  • the Applicant has identified a solution to this significant and worldwide problem. Specifically, combinations of four or more known antibiotics, surprisingly identified to have synergy against gram-negative and/or gram-positive bacteria. Such combinations have been found to kill antimicrobial-resistant bacteria, also termed drug-resistant bacteria, and avoid the development of antimicrobial resistance.
  • the four or more known antibiotics are defined in the appended claims and described herein.
  • the time to approval and the cost involved is much less than NCEs.
  • the time is, for example, about 5 years, and no more than $50M is needed to produce one new product. Since far fewer fail in development, the accumulated success/fail costs are about $130M for one CAD compared to $3.8 billion for each NCE.
  • the number of combinations required can be reduced by virtue of CADs having activity against a broad range of different infective species and can rejuvenate a single, unusable antibiotic due to antimicrobial resistance within a CAD with much higher activity against these antimicrobial resistant strains and avoid future antimicrobial resistance developing.
  • the CAD technology moves from 4% of high income countries for NCEs to about 0.005% GDP, allowing all high, middle and even low income countries to contribute as well as benefit.
  • the Applicant has revealed that the concentration of each antimicrobial agent of the combination is active at a very low concentration, for example, as low as 1/16 th of the agent’s MICmono- Thus, it may advantageously be possible to reduce any potential burden of toxicity by using lower amounts of each antimicrobial agent in the combination than e.g. for a monotherapy.
  • WO2015/114340 describes the use of zidovudine in combination with a polymyxin selected from colistin or polymyxin B, an anti-tuberculosis antibiotic selected from rifampicin, rifapentine or rifabutin and optionally piperine, for treating a microbial infection.
  • W02018/011562 describes a combination comprising zidovudine and a carbapenem, optionally with a polymyxin selected from polymyxin B and polymyxin E. The present invention does not therefore encompass these previously identified combinations of the Applicant.
  • Synergy is not predictable or expected when two or more actives are used in combination. Synergy in the context of antimicrobial drugs is measured in a number of ways that conform to the generally accepted opinion that “synergy is an effect greater than additive”. One of the ways to assess whether synergy has been observed is to use the “chequerboard” technique. This is a well-accepted method that leads to the generation of a value called the fractional inhibitory concentration index (FICI). Orhan et al., J. Clin. Microbiol.
  • FICI fractional inhibitory concentration index
  • FICI or fractional inhibitory concentration index is the sum of the FICs of each antimicrobial when used in combination.
  • the FIC or fractional inhibitory concentration of an antimicrobial in a combination is the MIC of the antimicrobial in the combination divided by the MIC of the same antimicrobial when used alone.
  • Minimum inhibitory concentrations are defined in the art as the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight incubation.
  • the combinations are active against resistant bacteria (see the Examples herein).
  • the individual antimicrobial agents in these combinations are notably active in many cases at concentrations significantly below the MIC when used alone.
  • the present inventors devised such a method. This method is applicable for any combination with “n” antimicrobial agents.
  • the inventors opted for this expression because it more closely aligns with the 2-mer synergy levels.
  • the same FIC scale as used for 2-mers was applied: synergy is observed when FIC is ⁇ 0.5.
  • An “Additive” effect is observed when FIC is 0.5 to ⁇ 1.
  • Indifference is observed when FIC is 1 to ⁇ 2.
  • Antagonism is observed when FIC is 2 to 4.
  • Synergy can be expressed as “ZFIC ⁇ 0.25 x n”.
  • the present invention provides a combination as defined in the appended claims.
  • This combination comprises at least four antimicrobial agents selected from rifampicin, levofloxacin, polymyxin E, polymyxin B, doxycycline, ceftazidime, and pharmaceutically acceptable derivatives thereof.
  • the combination includes ceftazidime, doxycycline, or a pharmaceutically acceptable derivative thereof.
  • the pharmaceutically acceptable derivative of polymyxin E may be defined as colistin sulfate, colistin methanesulfonate, or colistin methane sulfonate sodium.
  • the present invention provides the combinations defined herein for use in treating a bacterial infection.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the combination defined herein and a pharmaceutically acceptable adjuvant, diluent or carrier.
  • the pharmaceutical composition may be for use in the treatment of a bacterial infection.
  • the present invention provides a product comprising at least four antimicrobial agents selected from rifampicin, levofloxacin, polymyxin E, polymyxin B, doxycycline, ceftazidime, and pharmaceutically acceptable derivatives thereof, as a combined preparation for simultaneous, separate or sequential use in treating a bacterial infection.
  • the product includes ceftazidime, doxycycline, or a pharmaceutical acceptable derivative thereof. This means that the remaining antimicrobial agents in the product are selected from polymyxin E, polymyxin B, levofloxacin and rifampicin, or a pharmaceutically acceptable derivative thereof.
  • the pharmaceutically acceptable derivative of polymyxin E may be defined as colistin sulfate, colistin methanesulfonate, or colistin methane sulfonate sodium.
  • the present invention provides the use of a first antimicrobial agent in combination with at least a second, third and fourth antimicrobial agents in the manufacture of a medicament for synergistically treating a gram-negative or gram-positive bacterial infection.
  • the first antimicrobial agent is rifampicin or a pharmaceutically acceptable derivative thereof.
  • the second, third and fourth antimicrobial agents are selected from levofloxacin, polymyxin E, polymyxin B, doxycycline, ceftazidime, and pharmaceutically acceptable derivatives thereof.
  • the present invention provides the use of a first antimicrobial agent in combination with at least a second, third and fourth antimicrobial agents in the manufacture of a medicament for synergistically treating a gram-negative or gram-positive bacterial infection.
  • the first antimicrobial agent is levofloxacin or a pharmaceutically acceptable derivative thereof.
  • the second, third and fourth antimicrobial agents are selected from rifampicin, polymyxin E, polymyxin B, doxycycline, ceftazidime, and pharmaceutically acceptable derivatives thereof.
  • the present invention provides the use of a first antimicrobial agent in combination with at least a second, third and fourth antimicrobial agents in the manufacture of a medicament for synergistically treating a gram-negative or gram-positive bacterial infection.
  • the first antimicrobial agent is polymyxin E or B or a pharmaceutically acceptable derivative thereof.
  • the second, third and fourth antimicrobial agents are selected from levofloxacin, rifampicin, doxycycline, ceftazidime, and pharmaceutically acceptable derivatives thereof.
  • the present invention provides the use of a first antimicrobial agent in combination with at least a second, third and fourth antimicrobial agents in the manufacture of a medicament for synergistically treating a gram-negative or gram-positive bacterial infection.
  • the first antimicrobial agent is doxycycline or a pharmaceutically acceptable derivative thereof.
  • the second, third and fourth antimicrobial agents are selected from levofloxacin, polymyxin E, polymyxin B, rifampicin, ceftazidime, and pharmaceutically acceptable derivatives thereof.
  • the present invention provides the use of a first antimicrobial agent in combination with at least a second, third and fourth antimicrobial agents in the manufacture of a medicament for synergistically treating a gram-negative or gram-positive bacterial infection.
  • the first antimicrobial agent is ceftazidime or a pharmaceutically acceptable derivative thereof.
  • the second, third and fourth antimicrobial agents are selected from levofloxacin, polymyxin E, polymyxin B, doxycycline, rifampicin, and pharmaceutically acceptable derivatives thereof.
  • the present invention provides a method of treating a gramnegative or gram-positive bacterial infection, wherein the method comprises administering a pharmaceutically effective amount of a combination comprising at least four antimicrobial agents selected from rifampicin, levofloxacin, polymyxin E, polymyxin B, doxycycline, ceftazidime, and pharmaceutically acceptable derivatives thereof.
  • the expressions “combination of’ and “in combination with” cover separate, sequential and simultaneous administration of the agents. Unless specified to the contrary, the expressions are also intended to exclude any additional actives, e.g. “a combination comprising at least four antimicrobial agents” means that the defined agents are administered separately, sequentially or simultaneously but that no other actives are administered.
  • agents When the agents are administered sequentially, either rifampicin, levofloxacin, polymyxin E, polymyxin B, doxycycline, or ceftazidime may be administered first. When administration is simultaneous, the agents may be administered either in the same or a different pharmaceutical composition. In preferred embodiments, the agents are administered sequentially or simultaneously.
  • the combinations of the present invention may be used to treat gram-positive or gram-negative bacterial infections.
  • they may be used to kill multiplying and/or clinically latent bacteria associated with such infections, preferably multiplying bacteria associated with such infections, e.g. multiplying bacteria associated with Gram-negative bacterial infections.
  • References herein to the treatment of a bacterial infection therefore include killing multiplying and/or clinically latent microorganisms associated with such infections.
  • kill means a loss of viability as assessed by a lack of metabolic activity.
  • clinical latent bacteria means bacteria that is metabolically active but has a growth rate that is below the threshold of infectious disease expression.
  • the threshold of infectious disease expression refers to the growth rate threshold below which symptoms of infectious disease in a host are absent.
  • clinically latent bacteria can be determined by several methods known to those skilled in the art; for example, by measuring mRNA levels in the bacteria or by determining their rate of uridine uptake.
  • clinically latent bacteria when compared to bacteria under logarithmic growth conditions (in vitro or in vivo), possess reduced but still significant levels of:
  • mRNA e.g. from 0.0001 to 50%, such as from 1 to 30, 5 to 25 or 10 to 20%, of the level of mRNA
  • uridine e.g. [3H]uridine
  • uptake e.g. from 0.0005 to 50%, such as from 1 to 40, 15 to 35 or 20 to 30% of the level of [3H]uridine uptake).
  • Clinically latent bacteria typically possess a number of identifiable characteristics. For example, they may be viable but non-culturable; i.e. they cannot typically be detected by standard culture techniques, but are detectable and quantifiable by techniques such as broth dilution counting, microscopy, or molecular techniques such as polymerase chain reaction.
  • clinically latent bacteria are phenotypically tolerant, and as such are sensitive (in log phase) to the biostatic effects of conventional antimicrobial agents (i.e. bacteria for which the minimum inhibitory concentration (MIC) of a conventional antimicrobial is substantially unchanged); but possess drastically decreased susceptibility to drug-induced killing (e.g. bacteria for which, with any given conventional antimicrobial agent, the ratio of minimum microbiocidal concentration (e.g. minimum bactericidal concentration, MBC) to MIC is 10 or more).
  • conventional antimicrobial agents i.e. bacteria for which the minimum inhibitory concentration (MIC) of a conventional antimicrobial is substantially unchanged
  • drug-induced killing e.g. bacteria for which,
  • one or more of the aforementioned combinations is used to treat a bacterial infection, in particular the combinations may be used to kill multiplying and/or clinically latent bacteria associated with the bacterial infection.
  • bacteria and derivatives thereof, such as “bacterial infection”
  • Gram-positive cocci such as Staphylococci (e.g. Staph, aureus, Staph, epidermidis, Staph, saprophyticus, Staph, auricularis, Staph, capitis capitis, Staph, c. ureolyticus, Staph, caprae, Staph, cohnii cohnii, Staph, c. urealyticus, Staph, equorum, Staph, gallinarum, Staph, haemolyticus, Staph, hominis hominis, Staph, h.
  • Staphylococci e.g. Staph, aureus, Staph, epidermidis, Staph, saprophyticus, Staph, auricularis, Staph, capitis capitis, Staph, c. ureolyticus, Staph, caprae, Staph, cohnii cohni
  • Streptococci e.g. beta-haemolytic, pyogenic streptococci (such as Strept. agalactiae, Strept. canis, Strept. dysgalactiae dysgalactiae, Strept.
  • sanguinis Strept. cristatus, Strept. gordonii and Strept. parasanguinis
  • salivarius non-haemolytic, such as Strept. salivarius and Strept. vestibularis
  • mutans teeth-surface streptococci, such as Strept. criceti, Strept. mutans, Strept. ratti and Strept. sobrinus
  • Strept. acidominimus Strept. bovis
  • Strept. faecalis Strept. equinus
  • Enterococci e.g. Enterococcus avium, Enterococcus casseliflavus, Enterococcus cecorum, Enterococcus dispar, Enterococcus durans, Enterococcus faecalis, Enterococcus faecium, Enterococcus flavescens, Enterococcus gallinarum, Enterococcus hirae, Enterococcus malodoratus, Enterococcus mundtii, Enterococcus pseudoavium, Enterococcus raffinosus and Enterococcus solitariusy Bacillaceae, such as Bacillus anthracis, Bacillus subtilis, Bacillus thuringiensis, Bacillus stearothermophilus and Bacillus cereus',
  • Gram-negative cocci such as Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria cinerea, Neisseria elongata, Neisseria flavescens, Neisseria lactamica, Neisseria mucosa, Neisseria sicca, Neisseria subflava and Neisseria weaverr', Enterobacteriaceae, such as Escherichia coli, Enterobacter (e.g. Enterobacter aerogenes, Enterobacter agglomerans and Enterobacter cloacae), Citrobacter (such as Citrob. freundii and Citrob. divernis), Hafnia (e.g.
  • Hafnia alvei Erwinia (e.g. Erwinia persicinus), Morganella (e.g. Morganella morganii), Salmonella (Salmonella enterica and Salmonella typhi), Shigella (e.g. Shigella dysenteriae, Shigella flexneri, Shigella boydii and Shigella sonnei), Klebsiella (e.g.
  • Serratia marcescens and Serratia liquifaciens and Yersinia (e.g. Yersinia enterocolitica, Yersinia pestis and Yersinia pseudotuberculosis
  • Helicobacter e.g. Helicobacter pylori, Helicobacter cinaedi and Helicobacter fennelliae Acinetobacter (e.g. A. baumanii, A. calcoaceticus, A. haemolyticus, A. johnsonii, A. junii, A. Iwoffi and A. radioresistens
  • Pseudomonas e.g. Ps. aeruginosa, Ps.
  • maltophilia (Stenotrophomonas maltophilia), Ps. alcaligenes, Ps. chlororaphis, Ps. fluorescens, Ps. luteola. Ps. mendocina, Ps. monteilii, Ps. oryzi ha bitans, Ps. pertocinogena, Ps. pseudalcaligenes, Ps. putida and Ps. stutzeri Bacteriodes fragilis', Peptococcus (e.g. Peptococcus niger Peptostreptococcus; Clostridium (e.g. C. perfringens, C. difficile, C. botulinum, C.
  • Peptococcus e.g. Peptococcus niger Peptostreptococcus
  • Clostridium e.g. C. perfringens, C. difficile, C. botulinum, C.
  • Mycoplasma e.g. M. pneumoniae, M. hominis, M. genitalium and M. urealyticum Mycobacteria (e.g.
  • Mycobacterium tuberculosis Mycobacterium avium, Mycobacterium fortuitum, Mycobacterium marinum, Mycobacterium kansasii, Mycobacterium chelonae, Mycobacterium abscessus, Mycobacterium leprae, Mycobacterium smegmitis, Mycobacterium africanum, Mycobacterium alvei, Mycobacterium asiaticum, Mycobacterium aurum, Mycobacterium bohemicum, Mycobacterium bovis, Mycobacterium branded, Mycobacterium brumae, Mycobacterium celatum, Mycobacterium chubense, Mycobacterium confluentis, Mycobacterium conspicuum, Mycobacterium cookii, Mycobacterium flavescens, Mycobacterium gadium, Mycobacterium gastri, Mycobacterium genavense, Mycobacterium gordonae, Mycobacterium goodii, Mycobacterium haemophilum,
  • Brucella abortus Brucella canis, Brucella melintensis and Brucella suis
  • Campylobacter e.g. Campylobacter jejuni, Campylobacter coli, Campylobacter lari and Campylobacter fetus
  • Listeria monocytogenes Vibrio (e.g.
  • Vibrio cholerae and Vibrio parahaemolyticus Vibrio alginolyticus, Vibrio carchariae, Vibrio fluvialis, Vibrio furnissii, Vibrio hollisae, Vibrio metschnikovii, Vibrio mimicus and Vibrio vulnificus); Erysipelothrix rhusopathiae; Corynebacteriaceae (e.g. Corynebacterium diphtheriae, Corynebacterium jeikeum and Corynebacterium urealyticum); Spirochaetaceae, such as Borrelia (e.g.
  • Pasteurella e.g. Pasteurella aerogenes, Pasteurella bettyae, Pasteurella canis, Pasteurella dagmatis, Pasteurella gallinarum, Pasteurella haemolytica, Pasteurella multocida multocida, Pasteurella multocida gallicida, Pasteurella multocida septica, Pasteurella pneumotropica and Pasteurella stomatis
  • Bordetella e.g.
  • Nocardiaceae such as Nocardia (e.g. Nocardia asteroides and Nocardia brasiliensis); Rickettsia (e.g. Ricksettsii or Coxiella burnetii); Legionella (e.g.
  • Capnocytophaga e.g. Capnocytophaga canimorsus, Capnocytophaga cynodegmi, Capnocytophaga gingivalis, Capnocytophaga granulosa, Capnocytophaga haemolytica, Capnocytophaga ochracea and Capnocytophaga spumbleay Bartonella (Bartonella bacilliformis, Bartonella clarridgeiae, Bartonella elizabethae, Bartonella henselae, Bartonella quintana and Bartonella vinsonii arupensisy Leptospira (e.g.
  • Prevotella bivia Prevotella buccae, Prevotella corporis, Prevotella dentalis (Mitsuokella dentalis), Prevotella denticola, Prevotella disiens, Prevotella enoeca, Prevotella heparinolytica, Prevotella intermedia, Prevotella loeschii, Prevotella melaninogenica, Prevotella nigrescens, Prevotella oralis, Prevotella oris, Prevotella oulora, Prevotella tannerae, Prevotella venoralis and Prevotella zoogleoformansy Porphyromonas (e.g.
  • F. gonadiaformans e. mortiferum, F. naviforme, F. necrogenes, F. necrophorum necrophorum, F.
  • Chlamydia e.g. Chlamydia trachomatisy Cryptosporidium (e.g. C. parvum, C. hominis, C. cam's, C. felis, C. meleagridis and C. murisy Chlamydophila (e.g.
  • Chlamydophila abortus Chlamydia psittaci
  • Chlamydophila pneumoniae Chlamydia pneumoniae
  • Chlamydophila psittaci Chlamydophila psittaci
  • Leuconostoc e.g. Leuconostoc citreum, Leuconostoc cremoris, Leuconostoc dextranicum, Leuconostoc lactis, Leuconostoc mesenteroides and Leuconostoc pseudomesenteroidesy Gemella (e.g.
  • Gemella bergeri, Gemella haemolysans, Gemella morbillorum and Gemella sanguinisy Aeromonas e.g. Aeromonas hydrophila, Aeromonas caviae and Aeromonas veronii biovar sobriay and Ureaplasma (e.g. Urea plasma parvum and Ureaplasma urealyticum).
  • the combinations of the invention are synergistic against gram-positive or gram-negative bacteria selected from:
  • Gram-negatives Enterobacteriaceae, Enterobacter spp, Pseudomonas spp, Acinetobacterspp, Shigella spp, Salmonella spp, Burkholderia stenotrophomonas, Citrobacter spp, Serratia spp, Proteus spp, Morganella spp, Providencia spp, Haemophilus spp, Aeromonas spp, Pasteurella spp, Brucella spp, Helicobacter spp, Campylobacter spp, Franciella tularensis, Legionella spp, Vibrio spp, Neisseria spp, Mycobacterium spp, Yersinia pestis, Rickettsia spp.
  • Gram-positives Staphylococcus spp, Enterococcus spp, Streptococcus spp, Bacillus anthracis.
  • the Gram-negatives may, for example be: Enterobacteriaceae, such as Escherichia coli ; Enterobacter (e.g. Enterobacter aerogenes, Enterobacter agglomerans and Enterobacter cloacae) ; Citrobacter (such as Citrob. freundii and Citrob. divernis) ; Pseudomonas (e.g. Ps. aeruginosa, Ps. maltophilia (Stenotrophomonas maltophilia), Ps. alcaligenes, Ps. chlororaphis, Ps. fluorescens, Ps. luteola. Ps. mendocina, Ps.
  • Enterobacteriaceae such as Escherichia coli
  • Enterobacter e.g. Enterobacter aerogenes, Enterobacter agglomerans and Enterobacter cloacae
  • Citrobacter such as Citrob. freundii and Cit
  • Iwoffi and A. radioresistensy Morganella e.g. Morganella morganii
  • Salmonella Salmonella enterica and Salmonella typhi
  • Shigella e.g. Shigella dysenteriae, Shigella flexneri, Shigella boydii and Shigella sonnei
  • Klebsiella e.g. Klebs, pneumoniae, Klebs, oxytoca, Klebs, ornitholytica, Klebs. planticola, Klebs. ozaenae, Klebs. terrigena, Klebs.
  • granulomatis Calymmatobacterium granulomatis and Klebs, rhinoscleromatis
  • Burkholderia stenotrophomonas Francisella tularensis
  • Serratia e.g. Serratia marcescens and Serratia liquifaciens
  • Proteus e.g. Pr. mirabilis, Pr. rettgeri and Pr. vulgaris
  • Providencia e.g. Providencia alcalifaciens, Providencia rettgeri and Providencia stuartii
  • Haemophilus e.g.
  • Aeromonas e.g. Aeromonas hydrophila, Aeromonas caviae and Aeromonas veronii biovar sobria
  • Pasteurella e.g.
  • Legionalla anisa Legionalla birminghamensis, Legionalla bozemanii, Legionalla nucleophilii, Legionalla dumoffii, Legionalla feeleii, Legionalla gormanii, Legionalla hackeliae, Legionalla israelensis, Legionalla jordanis, Legionalla lansingensis, Legionalla longbeachae, Legionalla maceachernii, Legionalla micdadei, Legionalla oakridgensis, Legionalla pneumophila, Legionalla sainthelensi, Legionalla tucsonensis and Legionalla wadsworthii Vibrio (e.g.
  • Vibrio cholerae and Vibrio parahaemolyticus Vibrio alginolyticus, Vibrio carchariae, Vibrio fluvialis, Vibrio furnissii, Vibrio hollisae, Vibrio metschnikovii, Vibrio mimicus and Vibrio vulnificusy Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria cinerea, Neisseria elongata, Neisseria flavescens, Neisseria lactamica, Neisseria mucosa, Neisseria sicca, Neisseria subflava and Neisseria weaverr', Mycobacteria (e.g.
  • Mycobacterium tuberculosis Mycobacterium avium, Mycobacterium fortuitum, Mycobacterium marinum, Mycobacterium kansasii, Mycobacterium chelonae, Mycobacterium abscessus, Mycobacterium leprae, Mycobacterium smegmitis, Mycobacterium africanum, Mycobacterium alvei, Mycobacterium asiaticum, Mycobacterium aurum, Mycobacterium bohemicum, Mycobacterium bovis, Mycobacterium branded, Mycobacterium brumae, Mycobacterium celatum, Mycobacterium chubense, Mycobacterium confluentis, Mycobacterium conspicuum, Mycobacterium cookii, Mycobacterium flavescens, Mycobacterium gadium, Mycobacterium gastri, Mycobacterium genavense, Mycobacterium gordonae, Mycobacterium goodii, Mycobacterium haemophilum,
  • the Gram-positives may, for example, be Staphylococci (e.g. Staph, aureus, Staph, epidermidis, Staph, saprophyticus, Staph, auricularis, Staph, capitis capitis, Staph, c. ureolyticus, Staph, caprae, Staph, cohnii cohnii, Staph, c. urealyticus, Staph, equorum, Staph, gallinarum, Staph, haemolyticus, Staph, hominis hominis, Staph, h.
  • Staphylococci e.g. Staph, aureus, Staph, epidermidis, Staph, saprophyticus, Staph, auricularis, Staph, capitis capitis, Staph, c. ureolyticus, Staph, caprae, Staph, cohnii
  • Streptococci e.g. beta-haemolytic, pyogenic streptococci (such as Strept. agalactiae, Strept. canis, Strept. dysgalactiae dysgalactiae, Strept.
  • sanguinis Strept. cristatus, Strept. gordonii and Strept. parasanguinis
  • salivarius non-haemolytic, such as Strept. salivarius and Strept. vestibularis
  • mutans teeth-surface streptococci, such as Strept. criceti, Strept. mutans, Strept. ratti and Strept. sobrinus
  • Strept. acidominimus Strept. bovis
  • Strept. faecalis Strept. equinus
  • Enterococci e.g. Enterococcus avium, Enterococcus casseliflavus, Enterococcus cecorum, Enterococcus dispar, Enterococcus durans, Enterococcus faecalis, Enterococcus faecium, Enterococcus flavescens, Enterococcus gallinarum, Enterococcus hirae, Enterococcus malodoratus, Enterococcus mundtii, Enterococcus pseudoavium, Enterococcus raffinosus and Enterococcus solitarius Bacillus anthracis.
  • Enterococci e.g. Enterococcus avium, Enterococcus casseliflavus, Enterococcus cecorum, Enterococcus dispar, Enterococcus durans, Enterococcus faecalis, Enterococcus faecium, Enterococcus
  • the bacterial infections treated by the combinations described herein are Gram-negative bacterial infections.
  • Particular Gram-negative bacteria that may be treated using a combination of the invention include:
  • Enterobacteriaceae such as Escherichia coli, Klebsiella (e.g. Klebs, pneumoniae and Klebs, oxytoca) and Proteus (e.g. Pr. mirabilis, Pr. rettgeri and Pr. vulgaris), Haemophilus influenzae’, Mycobacteria, such as Mycobacterium tuberculosis; and Enterobacter (e.g. Enterobacter cloacae).
  • the bacteria are Enterobacteriaceae, such as Escherichia coli and Klebsiella (e.g. Klebs, pneumoniae and Klebs, oxytoca).
  • Escherichia coli and Klebs, pneumoniae (e.g. Klebs, pneumoniae subsp. pneumoniae).
  • the combination of the present invention is particularly beneficial in treating (multi)- drug-resistant ((M)DR) bacteria.
  • drug resistance most often builds up to carbapenemase i.e. carbapenemase-resistant strains and “extended spectrum p-lactamase” (ESBL) strains for example New Delhi Metallo-beta-lactamase-1 (NDM-1) resistant Klebs. Pneumoniae, and NDM-1 E.coli
  • ESBL extended spectrum p-lactamase
  • NDM-1 E.coli New Delhi Metallo-beta-lactamase-1
  • the combination of the present invention is also particularly effective against carbapenemase-producing Enterobacteriaceae (CPE).
  • Other drug-resistant strains may also be used, such as colistin-resistant strains, and carbapenemase-resistant strains of bacteria other than Enterobacteriaceae including carbapenem-resistant Acinetobacter and carbapenem-resistant pseudomonas organisms carrying the blaKPC gene.
  • the combination of the present invention is beneficial against the ESKAPE pathogens.
  • ESKAPE pathogens These are six highly virulent and typically antibiotic resistant bacterial pathogens including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter bacumannii, Pseudomonas aeruginosa, and Enterobacter spp.
  • This group of Gram-positive and Gram-negative bacteria can evade or “escape” commonly used antibiotics due to their increasing multi-drug resistance.
  • the combination of the present invention is beneficial against (M)DR strains of the ESKAPE pathogens.
  • the combinations of the present invention may have a broader spectrum of activity than a monotherapy or combination of only two actives.
  • various combinations may be efficacious against at least Acinetobacter, Pseudomonas and Enterobacteriaceae, which have been identified by the World Health Organisation as including multidrug resistant bacteria for which new antibiotics are critically needed.
  • the combinations of the present invention may be used to treat infections associated with any of the above-mentioned bacterial organisms, and in particular they may be used for killing multiplying and/or clinically latent microorganisms associated with such an infection, e.g. an ESKAPE pathogen bacterial infection.
  • the combinations of the present invention are effective in treating infections caused by (1) Carbapenem-resistant E.coli, Klebsiella spp., Acinetobacter spp. , Pseudomonas aeruginosa, Serratia spp, or Proteus, (2) MRSA, Vancomycin resistant Staphylococcus aureus (VRSA), Vancomycin resistant Enterococcus faecium (VRE), Clarithromycin resistant Helicobacter pylori, or Quinolone resistant Salmonella spp., or (3) penicillin resistant Streptococcus pneumoniae, Ampicillin resistant Haemophilus influenzae, or quinolone resistant Shigella spp.
  • the combinations of the present invention are effective in treating infections caused by Acinetobacter baumanii, Pseudomonas aeruginosa, or MRSA.
  • tuberculosis e.g. pulmonary tuberculosis, non-pulmonary tuberculosis (such as tuberculosis lymph glands, genito-urinary tuberculosis, tuberculosis of bone and joints, tuberculosis meningitis) and miliary tuberculosis
  • anthrax abscesses, acne vulgaris, actinomycosis, asthma, bacilliary dysentery, bacterial conjunctivitis, bacterial keratitis, bacterial vaginosis, botulism, Buruli ulcer, bone and joint infections
  • bronchitis acute or chronic
  • brucellosis burn wounds, cat scratch fever, cellulitis, chancroid, cholangitis, cholecystitis, cutaneous diphtheria, cystic fibrosis, cystitis, diffuse panbronchiolitis, dip
  • MSSA MRSA
  • Staph epidermidis
  • Particular conditions which may be treated using the combination of the present invention also include those which are caused by Gram-negative bacteria such as abscesses, asthma, bacilliary dysentery, bacterial conjunctivitis, bacterial keratitis, bacterial vaginosis, bone and joint infections, bronchitis (acute or chronic), brucellosis, burn wounds, cat scratch fever, cellulitis, chancroid, cholangitis, cholecystitis, cystic fibrosis, cystitis, nephritis, diffuse panbronchiolitis, dental caries, diseases of the upper respiratory tract, empyema, endocarditis, endometritis, enteric fever, enteritis, epididymitis, epiglottitis, eye infections, furuncles, gardnerella vaginitis, gastrointestinal infections (gastroenteritis), genital infections, gingivitis, gonorrhoea, granuloma
  • opthalmia neonatorum osteomyelitis
  • otitis e.g. otitis externa and otitis media
  • orchitis pancreatitis, paronychia, pelveoperitonitis, peritonitis, peritonitis with appendicitis, pharyngitis, pleural effusion, pneumonia, postoperative wound infections, postoperative gas gangrene, prostatitis, pseudomembranous colitis, psittacosis, pyelonephritis, Q fever, Ritter’s disease, salmonellosis, salpingitis, septic arthritis, septic infections, septicaemia, systemic infections, tonsillitis, trachoma, typhoid, urethritis, urinary tract infections, wound infections; or infections with, Escherichia coli, Klebs, pneumoniae, Klebs, oxytoca, Pr. mirabilis, Pr. rettgeri
  • the combinations of the present invention are used to treat acute or complicated urinary tract infections, acute or complicated skin and soft tissue infections, intraabdominal infections, upper respiratory tract infections, community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia, or bloodstream infections.
  • references herein to “treatment” extend to prophylaxis as well as the treatment of established diseases or symptoms.
  • pharmaceutically acceptable derivative means: (a) pharmaceutically acceptable salts; (b) solvates (including hydrates) and/or (c) prodrugs (where appropriate).
  • compositions of the compounds included in the combinations of the invention include suitable acid addition or base salts thereof.
  • suitable pharmaceutical salts may be found in Berge et al, J Pharm Sci, 66, 1-19 (1977).
  • Suitable acid addition salts include carboxylate salts (e.g. formate, acetate, trifluoroacetate, propionate, isobutyrate, heptanoate, decanoate, caprate, caprylate, stearate, acrylate, caproate, propiolate, ascorbate, citrate, glucuronate, glutamate, glycolate, a- hydroxybutyrate, lactate, tartrate, phenylacetate, mandelate, phenylpropionate, phenylbutyrate, benzoate, chlorobenzoate, methylbenzoate, hydroxy benzoate, methoxybenzoate, dinitrobenzoate, o-acetoxy benzoate, salicylate, nicotinate, isonicotinate, cinnamate, oxalate, malonate, succinate, suberate, sebacate, fumarate, malate, maleate, hydroxymaleate, hippurate, phthalate or
  • Suitable base salts include metal salts, e.g. sodium, calcium, and amine salts.
  • ceftazidime pentahydrate, colistin sulfate, polymyxin B sulfate, doxycycline hyclate (doxycycline hydrochloride hemiethanolate hemihydrate), doxycycline hydrochloride, doxycycline monohydrate, levofloxacin hemihydrate, and rifampicin N-oxide, are commercially available from Sigma Aldrich. Other suppliers are also known in the art.
  • prodrug means the antimicrobial compound, wherein one or more groups have been modified such that the modification may be reversed upon administration to a human or mammalian subject.
  • reversion is usually performed by an enzyme naturally present in such subject, though it is possible for a second agent to be administered together with such a prodrug in order to perform the reversion in vivo.
  • modifications include ester formation (for example, any of those described above), wherein the reversion may be carried out be an esterase etc.
  • Other such systems will be well known to those skilled in the art.
  • Polymyxin E or colistin is commercially available as a methanesulfonic acid derivative: colistimethate sodium or colistin sodium methanesulfonate (CMS).
  • CMS methanesulfonic acid derivative
  • Colistimethate sodium is a prodrug. It is produced by the reaction of colistin with formaldehyde and sodium bisulfite, which leads to the addition of a sulfomethyl group to the primary amines of colistin. In aqueous solutions it undergoes hydrolysis to form a complex mixture of partially sulfomethylated derivatives and colistin.
  • the invention includes the use of these pharmaceutically acceptable derivatives and prodrugs.
  • the invention includes the use of colistin and pharmaceutically acceptable derivatives thereof including colistin sulfate, colistimethate sodium and colistin sodium methanesulfonate.
  • the invention also includes where appropriate all enantiomers and tautomers of the compounds.
  • the skilled person will recognise compounds that possess optical properties (one or more chiral carbon atoms) or tautomeric characteristics.
  • the corresponding enantiomers and/or tautomers may be isolated or prepared by methods known in the art.
  • Some of the compounds included in the combinations of the invention may exist as stereoisomers and/or geometric isomers - e.g. they may possess one or more asymmetric and/or geometric centres and so may exist in two or more stereoisomeric and/or geometric forms.
  • the present invention contemplates the use of all the individual stereoisomers and geometric isomers of those inhibitor agents, and mixtures thereof.
  • the terms used in the claims encompass these forms, provided said forms retain the appropriate functional activity (though not necessarily to the same degree).
  • the present invention also includes all suitable isotopic variations of the compounds or pharmaceutically acceptable salts thereof.
  • An isotopic variation or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
  • isotopes that can be incorporated include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine and chlorine such as 2H, 3H, 13C, 14C, 15N, 170, 180, 31 P, 32P, 35S, 18F and 36CI, respectively.
  • isotopic variations for example, those in which a radioactive isotope such as 3H or 14C is incorporated, are useful in drug and/or substrate tissue distribution studies. Tritiated, i.e. , 3H, and carbon-14, i.e. , 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium, i.e., 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances. Isotopic variations can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.
  • the compounds for use in the combination of the present invention are commercially available and/or can be prepared by synthesis methods known in the art.
  • Ceftazidime is sold under the brand name Fortaz among others, and is a third- generation cephalosporin antibiotic used in the treatment of a number of bacterial infections. It has the following chemical structure:
  • Polymyxin E is also known as colistin. It is an antibiotic medication used as a lastresort treatment for multidrug-resistant Gram-negative infections including pneumonia. These may involve bacteria such as Pseudomonas aeruginosa, Klebsiella pneumoniae, or Acinetobacter. It comes in two forms: colistimethate sodium can be injected into a vein, injected into a muscle, or inhaled, and colistin sulfate is mainly applied to the skin or taken by mouth. It has the following chemical structure:
  • Polymyxin B sold under the brand name Poly-Rx among others, is an antibiotic used to treat meningitis, pneumonia, sepsis, and urinary tract infections. It can be given by injection into a vein, muscle or cerebrospinal fluid, or inhaled. It has the following chemical structure:
  • Doxycycline is a broad-spectrum tetracycline-class antibiotic used in the treatment of infections caused by bacteria and certain parasites. It is used to treat bacterial pneumonia, acne, chlamydia infections, Lyme disease, cholera, typhus, and syphilis. Doxycycline may be taken by mouth or by injection into a vein. It has the following chemical structure:
  • Levofloxacin sold under the brand name Levaquin among others, is an antibiotic medication used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. It is available by mouth, intravenously, and in eye drop form. It is the (S)-isomer of ofloxacin and has the following chemical structure:
  • Rifampicin also known as rifampin, is an ansamycin antibiotic used to treat several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires’ disease. Rifampicin may be given either by mouth or intravenously and has the following chemical structure:
  • the synergistic combination of the present invention includes four antimicrobial agents. These agents are grouped in the appended claims so as to cover the exemplified combinations in the most efficient manner.
  • the at least four antimicrobial agents are selected from rifampicin, polymyxin E, polymyxin B, doxycycline, ceftazidime, and pharmaceutically acceptable derivatives thereof.
  • the at least four antimicrobial agents are selected from levofloxacin, polymyxin B, polymyxin E, doxycycline, ceftazidime, and pharmaceutically acceptable derivatives thereof.
  • the at least four antimicrobial agents are selected from rifampicin, levofloxacin, doxycycline, ceftazidime, and pharmaceutically acceptable derivatives thereof.
  • the at least four antimicrobial agents are rifampicin, polymyxin E, doxycycline and ceftazidime, or a pharmaceutically acceptable derivative thereof.
  • the at least four antimicrobial agents are levofloxacin, polymyxin E, doxycycline and ceftazidime, or a pharmaceutically acceptable derivative thereof.
  • the at least four antimicrobial agents are rifampicin, levofloxacin, doxycycline, ceftazidime, or a pharmaceutically acceptable derivative thereof.
  • the at least four antimicrobial agents include at least ceftazidime, doxycycline, or a pharmaceutically acceptable derivative thereof.
  • the at least four antimicrobial agents include (i) ceftazidime or a pharmaceutically acceptable derivative thereof, (ii) doxycycline or a pharmaceutically acceptable derivative thereof, (iii) polymyxin E, polymyxin B, levofloxacin, or a pharmaceutically acceptable derivative thereof, and (iv) levofloxacin, rifampicin or a pharmaceutically acceptable derivative thereof, provided that (iii) and (iv) are different.
  • Compounds for use according to the invention may be administered as the raw material but are preferably provided in the form of pharmaceutical compositions.
  • the compounds may be used either as separate formulations or as a single combined formulation. When combined in the same formulation it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the formulation.
  • Formulations of the invention include those suitable for oral, parenteral (including subcutaneous e.g. by injection or by depot tablet, intrathecal, intramuscular e.g. by depot and intravenous), and rectal or in a form suitable for administration by inhalation or insufflation administration.
  • parenteral including subcutaneous e.g. by injection or by depot tablet, intrathecal, intramuscular e.g. by depot and intravenous
  • rectal or in a form suitable for administration by inhalation or insufflation administration may depend upon the condition and disorder of the patient.
  • the compositions of the invention are formulated for oral administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy e.g. as described in “Remington: The Science and Practice of Pharmacy", Lippincott Williams and Wilkins, 21 st Edition, (2005). Suitable methods include the step of bringing into association to active ingredients with a carrier which constitutes one or more excipients. In general, formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation. It will be appreciated that when the two active ingredients are administered independently, each may be administered by a different means.
  • the active ingredients may be present in a concentration from 0.1 to 99.5% (such as from 0.5 to 95%) by weight of the total mixture; conveniently from 30 to 95% for tablets and capsules and 0.01 to 50% (such as from 3 to 50%) for liquid preparations.
  • the concentration of each antimicrobial agent in the synergistic combination is equal to or less than the minimum inhibitory concentration in monotherapy for the bacteria against which the combination is being used (i.e. MICmono). Reference herein to “MIC” should therefore be understood as MICmono unless otherwise specified.
  • concentration of at least one of the antimicrobial agents in the synergistic combination is less than M ICmono, more preferably the concentration of at least two of the antimicrobial agents in the synergistic combination is less than M ICmono.
  • concentrations is advantageous because it avoids toxicity issues and the reduces the possibility of antimicrobial resistance developing vs one or more of the agents in the combination.
  • the concentration of ceftazidime is 1x MIC or less for the bacteria against which the combination is being used, the MIC being the minimum inhibitory concentration of ceftazidime when used alone against said bacteria, i.e. M ICmono.
  • the concentration of ceftazidime may be 0.5 x M ICmono or less for the bacteria against which the combination is being used. More preferably the concentration of ceftazidime is 0.25 x M ICmono or less for the bacteria against which the combination is being used. Most preferably, the concentration of ceftazidime is 0.125 x M ICmono or less for the bacteria against which the combination is being used.
  • the concentration of ceftazidime is as low as 0.0625 x M ICmono - equivalent to 1/16 th M ICmono - for the bacteria against which the combination is being used. In other embodiments, the concentration of ceftazidime is as low as 0.0039 x M ICmono - equivalent to 1/32 nd M ICmono - for the bacteria against which the combination is being used.
  • the ceftazidime concentration may be about 32 mg/L or less in a combination showing synergy against ESBL E.coli. In a preferred embodiment the ceftazidime concentration may be about 1 to about 32 mg/L in a combination showing synergy against ESBL E.coli.
  • the ceftazidime concentration may be about 32 mg/L or less in a combination showing synergy against KPC K.pneumoniae. In a preferred embodiment the ceftazidime concentration may be about 0.125 mg/L to about 32 mg/L in a combination showing synergy against KPC K.pneumoniae.
  • the concentration of doxycycline is 1x MICmono or less for the bacteria against which the combination is being used.
  • the concentration of doxycycline may be 0.5 x M ICmono or less for the bacteria against which the combination is being used.
  • the concentration of doxycycline may be 0.25 x M ICmono or less for the bacteria against which the combination is being used. Most preferably the concentration of doxycycline may be 0.125 x M ICmono or less for the bacteria against which the combination is being used.
  • the doxycycline concentration may be about 1 mg/L or less in a combination showing synergy against ESBL E.coli, preferably about 0.03 to about 1 mg/L.
  • the doxycycline concentration may be about 1 mg/L or less in a combination showing synergy against KPC K.pneumoniae, preferably about 0.03125 to about 1 mg/L.
  • ceftazidime is used at a concentration of about 1 to about 32 mg/L and doxycycline is used at a concentration of about 0.03 to about 1 mg/L in a combination showing synergy against ESBL E.coli.
  • ceftazidime is used at a concentration of about 0.125 to about 32 mg/L and doxycycline is used at a concentration of about 0.03125 to about 1 mg/L, more preferably 0.25 to about 32 mg/L in a combination showing synergy against KPC K.pneumoniae.
  • the concentration of rifampicin may be 1x M ICmono or less for the bacteria against which the combination is being used.
  • the concentration of rifampicin may be 0.5 x M ICmono or less for the bacteria against which the combination is being used. More preferably the concentration of rifampicin may be 0.25 x M ICmono or less for the bacteria against which the combination is being used. Most preferably the concentration of rifampicin may be 0.125 x M ICmono or less for the bacteria against which the combination is being used.
  • the concentration of rifampicin can be 0.0625 x M ICmono for the bacteria against which the combination is being used.
  • the rifampicin concentration may be about 4 mg/L or less in a combination showing synergy against ESBL E.coli, preferably about 0.125 to about 4 mg/L. In another example, the rifampicin concentration may be about 4 mg/L or less in a combination showing synergy against KPC Kpneumoniae, preferably about 0.125 mg/L to about 4 mg/L.
  • ceftazidime is used at a concentration of about 1 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.03 to about 1 mg/L
  • rifampicin is used at a concentration of about 0.125 to about 4 mg/L in a combination showing synergy against ESBL E.coli.
  • the ceftazidime concentration may be about 1 to about 32 mg/L
  • the doxycycline concentration may be about 0.06 to about 1 mg/L
  • the rifampicin concentration may be about 0.125 to about 4 mg/L in a combination showing synergy against ESBL E.coli.
  • ceftazidime is used at a concentration of about 1 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.03 to about 1 mg/L
  • rifampicin is used at a concentration of 1 to 4 mg/L in a combination showing synergy against ESBL E.coli.
  • ceftazidime is used at a concentration of about 1 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.03 to about 1 mg/L
  • rifampicin is used at a concentration of 0.125 to 4 mg/L in a combination showing synergy against ESBL E.coli.
  • ceftazidime is used at a concentration of about 8 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.03 to about 1 mg/L
  • rifampicin is used at a concentration of about 0.125 to about 4 mg/L in a combination showing synergy against ESBL E.coli.
  • ceftazidime may be used at a concentration of about 8 to about 32 mg/L
  • doxycycline may be used at a concentration of about 0.125 to about 1 mg/L
  • rifampicin is used at a concentration of about 0.125 to about 4 mg/L in a combination showing synergy against ESBL E.coli.
  • ceftazidime is used at a concentration of about 0.125 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.03125 to about 1 mg/L
  • rifampicin is used at a concentration of about 0.125 mg/L to about 4 mg/L in a combination showing synergy against KPC K.pneumoniae.
  • ceftazidime is used at a concentration of about 0.125 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.25 to about 1 mg/L
  • rifampicin is used at a concentration of about 0.125 mg/L to about 4 mg/L in a combination showing synergy against KPC K.pneumoniae.
  • ceftazidime is used at a concentration of about 0.125 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.25 to about 1 mg/L
  • rifampicin is used at a concentration of about 0.25 mg/L to about 4 mg/L in a combination showing synergy against KPC K.pneumoniae.
  • each of ceftazidime, doxycycline and rifampicin may also be expressed as factors of M ICmono-
  • ceftazidime may be used at a concentration of 1x M I Cmono or less
  • doxycycline may be used at a concentration of 1x M ICmono or less
  • rifampicin may be used at a concentration of 1x M ICmono or less.
  • ceftazidime may be used at a concentration of 1x M ICmono or less
  • doxycycline may be used at a concentration of 1x M ICmono or less
  • rifampicin may be used at a concentration of 0.125 to 1 x M ICmono.
  • ceftazidime may be used at a concentration of 0.5 x M ICmono or less
  • doxycycline may be used at a concentration of 1x M ICmono or less
  • rifampicin is used at a concentration of 1 x M ICmono or less.
  • ceftazidime may be used at a concentration of 1 x M ICmono or less
  • doxycycline may be used at a concentration of 0.5x M ICmono or less
  • rifampicin is used at a concentration of 1 x M ICmono or less.
  • the concentration of polymyxin E or polymyxin B may be 1x M ICmono or less for the bacteria against which the combination is being used.
  • the concentration of polymyxin E or polymyxin B may be 0.5 x M ICmono or less for the bacteria against which the combination is being used. More preferably the concentration of polymyxin E or polymyxin B may be 0.25 x M ICmono or less for the bacteria against which the combination is being used. Most preferably the concentration of polymyxin E or polymyxin B may be 0.125 x M ICmono or less for the bacteria against which the combination is being used.
  • the polymyxin E or polymyxin B concentration may be about 2 mg/L or less in a combination showing synergy against ESBL E.coli, preferably about 0.06 to about 2 mg/L.
  • the polymyxin E or polymyxin B concentration may be about 1 mg/L or less in a combination showing synergy against KPC K.pneumoniae, preferably about 0.125 mg/L to about 1 mg/L.
  • concentration ranges for polymyxin E/B may be combined with those for each of ceftazidime, doxycycline and rifampicin above.
  • ceftazidime is used at a concentration of about 1 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.03 to about 1 mg/L
  • rifampicin is used at a concentration of about 0.125 to about 4 mg/L
  • polymyxin E/B is used at a concentration of about 0.06 to about 2 mg/L in a combination showing synergy against ESBL E.coli.
  • the ceftazidime concentration may be about 1 to about 32 mg/L
  • the doxycycline concentration may be about 0.125 to about 1 mg/L
  • the rifampicin concentration may be about 0.125 to about 4 mg/L
  • the polymyxin E/B concentration may be about 0.125 to about 2 mg/L in a combination showing synergy against ESBL E.coli.
  • ceftazidime is used at a concentration of about 8 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.03 to about 1 mg/L
  • rifampicin is used at a concentration of about 0.125 to about 4 mg/L
  • polymyxin E/B is used at a concentration of about 0.06 to about 2 mg/L in a combination showing synergy against ESBL E.coli.
  • ceftazidime may be used at a concentration of about 8 to about 32 mg/L
  • doxycycline may be used at a concentration of about 0.125 to about 1 mg/L
  • rifampicin is used at a concentration of about 0.125 to about 4 mg/L
  • polymyxin E/B is used at a concentration of about 0.06 to about 2 mg/L in a combination showing synergy against ESBL E.coli.
  • ceftazidime is used at a concentration of about 1 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.03 to about 1 mg/L
  • rifampicin is used at a concentration of about 1 to 4 mg/L
  • polymyxin E/B is used at a concentration of about 0.06 to about 2 mg/L in a combination showing synergy against ESBL E.coli.
  • ceftazidime is used at a concentration of about 1 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.03 to about 1 mg/L
  • rifampicin is used at a concentration of about 0.125 to 4 mg/L
  • polymyxin E/B is used at a concentration of about 0.25 to about 2 mg/L in a combination showing synergy against ESBL E.coli.
  • ceftazidime is used at a concentration of about 4 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.03 to about 1 mg/L
  • rifampicin is used at a concentration of about 0.25 to about 4 mg/L
  • polymyxin E/B is used at a concentration of about 0.25 to about 2 mg/L in a combination showing synergy against ESBL E.coli.
  • ceftazidime is used at a concentration of about 0.125 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.03125 to about 1 mg/L
  • rifampicin is used at a concentration of about 0.125 mg/L to about 4 mg/L
  • polymyxin E/B is used at a concentration of about 0.125 mg/L to about 1 mg/L in a combination showing synergy against KPC K.pneumoniae.
  • ceftazidime is used at a concentration of about 0.125 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.03125 to about 1 mg/L
  • rifampicin is used at a concentration of about 0.125 mg/L to about 4 mg/L
  • polymyxin E/B is used at a concentration of about 0.125 mg/L to about 1 mg/L in a combination showing synergy against KPC K.pneumoniae.
  • ceftazidime is used at a concentration of about 0.125 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.25 to about 1 mg/L
  • rifampicin is used at a concentration of about 0.125 mg/L to about 4 mg/L
  • polymyxin E/B is used at a concentration of about 0.125 mg/L to about 1 mg/L in a combination showing synergy against KPC K.pneumoniae.
  • ceftazidime is used at a concentration of about 0.125 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.25 to about 1 mg/L
  • rifampicin is used at a concentration of about 0.25 mg/L to about 4 mg/L
  • polymyxin E/B is used at a concentration of about 0.125 mg/L to about 1 mg/L in a combination showing synergy against KPC K.pneumoniae.
  • each of ceftazidime, doxycycline, rifampicin and polymyxin E/B may also be expressed as factors of MICmono.
  • ceftazidime may be used at a concentration of 1x M ICmono or less
  • doxycycline may be used at a concentration of 1x M ICmono or less
  • rifampicin may be used at a concentration of 1x M ICmono or less
  • polymyxin E/B may be used at a concentration of 1x M ICmono or less.
  • ceftazidime may be used at a concentration of 1x M ICmono or less
  • doxycycline may be used at a concentration of 1x M ICmono or less
  • rifampicin may be used at a concentration of 0.0625 to 1 x M ICmono
  • polymyxin E/B may be used at a concentration of 0.0625 to 1 x M ICmono.
  • ceftazidime may be used at a concentration of 1x M ICmono or less
  • doxycycline may be used at a concentration of 1x M ICmono or less
  • rifampicin may be used at a concentration of 0.0625 to 1 x M ICmono
  • polymyxin E/B may be used at a concentration of 0.125 to 1 x M ICmono-
  • ceftazidime may be used at a concentration of 0.5 x M ICmono or less
  • doxycycline may be used at a concentration of 1x M ICmono or less
  • each of polymyxin E/B and rifampicin are used at a concentration of 1 x M ICmono or less.
  • ceftazidime may be used at a concentration of 1 x M ICmono or less
  • doxycycline may be used at a concentration of 0.5x M ICmono or less
  • each of polymyxin E/B and rifampicin are used at a concentration of 1 x M ICmono or less.
  • ceftazidime may be used at a concentration of 0.5 x M ICmono or less
  • doxycycline may be used at a concentration of 1x M ICmono or less
  • rifampicin is used at a concentration of 1x M ICmono or less
  • polymyxin E/B is used at a concentration of 0.125 to 1x M ICmono-
  • the concentration of levofloxacin is 1x M ICmono or less for the bacteria against which the combination is being used.
  • the concentration of levofloxacin may be 0.5 x M ICmono or less for the bacteria against which the combination is being used. More preferably the concentration of levofloxacin may be 0.25 x M ICmono or less for the bacteria against which the combination is being used. Most preferably, the concentration of levofloxacin is 0.125 x M ICmono or less for the bacteria against which the combination is being used.
  • the levofloxacin concentration may be about 8 mg/L or less in a combination showing synergy against ESBL E.coli, preferably about 0.25 to about 8 mg/L.
  • the concentration ranges for levofloxacin may be combined with those for each of ceftazidime and doxycycline.
  • ceftazidime is used at a concentration of about 1 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.03 to about 1 mg/L
  • levofloxacin is used at a concentration of about 0.25 to about 8 mg/L in a combination showing synergy against ESBL E.coli.
  • the ceftazidime concentration may be about 8 to about 32 mg/L
  • the doxycycline concentration may be about 0.03 to about 1 mg/L
  • the levofloxacin concentration may be about 0.25 to about 8 mg/L in a combination showing synergy against ESBL E.coli.
  • the ceftazidime concentration may be about 16 to about 32 mg/L
  • the doxycycline concentration may be about 0.03 to about 1 mg/L
  • the levofloxacin concentration may be about 0.25 to about 8 mg/L in a combination showing synergy against ESBL E.coli.
  • concentration ranges for ceftazidime, doxycycline and levofloxacin may also be combined with those for polymyxin E/B or rifampicin as set out below.
  • ceftazidime is used at a concentration of about 1 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.03 to about 1 mg/L
  • levofloxacin is used at a concentration of about 0.25 to about 8 mg/L
  • polymyxin E/B is used at a concentration of about 0.06 to about 2 mg/L in a combination showing synergy against ESBL E.coli.
  • the ceftazidime concentration may be about 4 to about 32 mg/L
  • the doxycycline concentration may be about 0.06 to about 1 mg/L
  • the levofloxacin concentration may be about 8 mg/L
  • the polymyxin E/B concentration may be about 0.125 to about 2 mg/L in a combination showing synergy against ESBL E.coli.
  • ceftazidime is used at a concentration of about 16 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.03 to about 1 mg/L
  • levofloxacin is used at a concentration of about 0.125 to about 4 mg/L
  • polymyxin E/B is used at a concentration of about 0.06 to about 2 mg/L in a combination showing synergy against ESBL E.coli.
  • concentrations of each of ceftazidime, doxycycline, levofloxacin and polymyxin E/B may also be expressed as factors of MICmono.
  • ceftazidime may be used at a concentration of 1x M ICmono or less
  • doxycycline may be used at a concentration of 1x M ICmono or less
  • levofloxacin may be used at a concentration of 1x M ICmono or less
  • polymyxin E/B may be used at a concentration of 1x M ICmono or less.
  • ceftazidime may be used at a concentration of 1x MICmono or less
  • doxycycline may be used at a concentration of 1x M ICmono or less
  • levofloxacin may be used at a concentration of 0.0625 to 1 x M ICmono
  • polymyxin E/B may be used at a concentration of 0.0625 to 1 x M ICmono-
  • ceftazidime may be used at a concentration of 0.5 x M ICmono to 1 x M ICmono
  • doxycycline may be used at a concentration of 1x M ICmono or less
  • each of polymyxin E/B and levofloxacin are used at a concentration of 1 x M ICmono or less.
  • ceftazidime is used at a concentration of about 1 to about 32 mg/L
  • doxycycline is used at a concentration of about 0.06 to about 1 mg/L
  • levofloxacin is used at a concentration of about 0.25 to about 8 mg/L
  • rifampicin is used at a concentration of about 0.03 to 1 mg/L in a combination showing synergy against ESBL E.coli.
  • the ceftazidime concentration may be about 2 to about 32 mg/L
  • the doxycycline concentration may be about 0.06 to about 1 mg/L
  • the levofloxacin concentration may be about 2 to about 8 mg/L
  • rifampicin is used at a concentration of about 0.03 to 1 mg/L in a combination showing synergy against ESBL E.coli.
  • the ceftazidime concentration may be about 16 to 32 mg/L
  • the doxycycline concentration may be about 0.06 to about 1 mg/L
  • the levofloxacin concentration may be about 4 to about 8 mg/L
  • rifampicin is used at a concentration of about 0.03 to 1 mg/L in a combination showing synergy against ESBL E.coli.
  • the ceftazidime concentration may be about 2 to about 32 mg/L
  • the doxycycline concentration may be about 0.06 to about 0.5 mg/L
  • the levofloxacin concentration may be about 0.25 to about 8 mg/L
  • the doxycycline concentration may be about 0.06 to about 1 mg/L
  • the levofloxacin concentration may be about 2 to about 8 mg/L
  • rifampicin is used at a concentration of about 0.03 to 1 mg/L in a combination showing synergy against ESBL E.coli.
  • the ceftazidime concentration may be about 16 to about 32 mg/L
  • the doxycycline concentration may be about 0.06 to about 1 mg/L
  • the levofloxacin concentration may be about 0.25 to about 8 mg/L
  • rifampicin is used at a concentration of about 0.03 to 1 mg/L in a combination showing synergy against ESBL E.coli..
  • each of ceftazidime, doxycycline, levofloxacin and rifampicin may also be expressed as factors of M ICmono.
  • ceftazidime may be used at a concentration of 1x M ICmono or less
  • doxycycline may be used at a concentration of 1x M ICmono or less
  • levofloxacin may be used at a concentration of 1x M ICmono or less
  • rifampicin may be used at a concentration of 1x M ICmono or less.
  • ceftazidime may be used at a concentration of 1x M ICmono or less
  • doxycycline may be used at a concentration of 1x M ICmono or less
  • levofloxacin may be used at a concentration of 1 x M ICmono
  • rifampicin may be used at a concentration of 1x M ICmono or less.
  • ceftazidime may be used at a concentration of 0.5 to 1 x MICmono
  • doxycycline may be used at a concentration of 1x MICmono
  • levofloxacin is used at a concentration of 1 x MICmono or less
  • rifampicin may be used at a concentration of 1x MICmono or less.
  • the lower limit for the MICmono ranges defined herein is not limited. Where one is not specified, it is preferably 1/512 th MICmono, 1/256 th MICmono, 1/128 th MICmono, 1/64 th MICmono, 1 /32 nd MICmono, or 0.0625 MICmono. For example, “0.5x MICmono or less” becomes “0.5 x MICmono to 0.0625 MICmono.
  • Formulations suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets (e.g. chewable tablets in particular for paediatric administration), each containing a predetermined amount of active ingredient; as powder or granules; as a solution or suspension in an aqueous liquid or non-aqueous liquid; or as an oil- in-water liquid emulsion or water-in-oil liquid emulsion.
  • the active ingredients may also be presented a bolus, electuary or paste.
  • a tablet may be made by compression or molding, optionally with one or more excipients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with other conventional excipients such as binding agents (e.g. syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch, polyvinylpyrrolidone and/or hydroxymethyl cellulose), fillers (e.g. lactose, sugar, microcrystalline cellulose, maize-starch, calcium phosphate and/or sorbitol), lubricants (e.g.
  • binding agents e.g. syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch, polyvinylpyrrolidone and/or hydroxymethyl cellulose
  • fillers e.g. lactose, sugar, microcrystalline cellulose, maize-
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient with an inert liquid diluent.
  • the tablets may be optionally coated or scored and may be formulated so as to provide controlled release (e.g. delayed, sustained, or pulsed release, or a combination of immediate release and controlled release) of the active ingredients.
  • the active ingredients may be incorporated into oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, syrups or elixirs.
  • Formulations containing the active ingredients may also be presented as a dry product for constitution with water or another suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents (e.g. sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxymethyl cellulose, carboxymethyl cellulose, aluminium stearate gel and/or hydrogenated edible fats), emulsifying agents (e.g. lecithin, sorbitan mono-oleate and/or acacia), non-aqueous vehicles (e.g. edible oils, such as almond oil, fractionated coconut oil, oily esters, propylene glycol and/or ethyl alcohol), and preservatives (e.g. methyl or propyl p-hydroxybenzoates and/or sorbic acid).
  • suspending agents e.g. sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxymethyl cellulose, carboxymethyl cellulose, aluminium stearate gel and/or hydrogenated edible fats
  • emulsifying agents e.g. lecithin,
  • Combinations for use according to the invention may be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredients.
  • the pack may, e.g. comprise metal or plastic foil, such as a blister pack.
  • compositions are intended for administration as three separate compositions these may be presented in the form of a twin pack.
  • compositions may also be prescribed to the patient in “patient packs” containing the whole course of treatment in a single package, usually a blister pack.
  • Patient packs have an advantage over traditional prescriptions, where a pharmacist divides a patients’ supply of a pharmaceutical from a bulk supply, in that the patient always has access to the package insert contained in the patient pack, normally missing in traditional prescriptions. The inclusion of the package insert has been shown to improve patient compliance with the physician’s instructions.
  • a patient pack comprising at least one active of the combination according to the invention and an information insert containing directions on the use of the combination of the invention.
  • a double pack comprising in association for separate administration, an antimicrobial agent, preferably having biological activity against clinically latent microorganisms, and one or more of the compounds disclosed herein preferably having biological activity against clinically latent microorganisms.
  • the amount of active ingredients required for use in treatment will vary with the nature of the condition being treated and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician. In general however, doses employed for adult human treatment will typically be in the range of 0.02 to 5000 mg per day, preferably 1 to 1500 mg per day. The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, e.g. as two, three or more sub-doses per day. [0139] This information would therefore be readily obtained and understood by the person skilled in the art.
  • Test procedures that may be employed to determine the biological (e.g. bactericidal or antimicrobial) activity of the active ingredients include those known to persons skilled in the art for determining:
  • methods for determining activity against clinically latent bacteria include a determination, under conditions known to those skilled in the art (such as those described in Nature Reviews, Drug Discovery 1, 895-910 (2002), the disclosures of which are hereby incorporated by reference), of Minimum Stationary-cidal Concentration (“MSC”) or Minimum Dormicidal Concentration (“MDC”) for a test compound.
  • MSC Minimum Stationary-cidal Concentration
  • MDC Minimum Dormicidal Concentration
  • W02000028074 describes a suitable method of screening compounds to determine their ability to kill clinically latent microorganisms.
  • a typical method may include the following steps:
  • the phenotypically resistant sub-population may be seen as representative of clinically latent bacteria which remain metabolically active in vivo and which can result in relapse or onset of disease.
  • methods for determining activity against log phase bacteria include a determination, under standard conditions (i.e. conditions known to those skilled in the art, such as those described in WO 2005014585, the disclosures of which document are hereby incorporated by reference), of Minimum Inhibitory Concentration (“MIC”) or Minimum Bactericidal Concentration (“MBC”) for a test compound. Specific examples of such methods are described below.
  • the antimicrobial agents were sourced from commercially available sources. They were prepared by being weighed and dissolved in water, PBS, DMSO or acidified water to a final concentration from 1-10 mg/mL. Antimicrobial solutions were diluted to 10x highest concentration used in the experiment and subsequently diluted 2x over a series not exceeding 11 serial dilutions. These left the operator with a maximum of 12 different, descending concentrations of the chosen antimicrobials.
  • Plates were sealed with lids and left to incubate for 16 hours, overnight. [0154] Plates were read at OD 6 oo in a 96-well plate reader. The OD values are reported for each combination below.
  • Example 1 Synergy between ceftazidime, doxycycline, colistin and rifampicin
  • Synergy is not a predictable result. Synergy is especially not predictable at concentrations below MIC or against MDR bacteria (ESBL E.coli); this means that the combinations are an important development in the fight against antimicrobial resistance. Surprisingly they are successful against bacteria that has an enzyme (ESBL) found in strains known not to be killed by many of the antibiotics that those skilled in the art use to treat infections.
  • ESBL enzyme
  • Example 4 Synergy between ceftazidime (ceft), doxycycline (doxy), rifampicin (rif) and colistin (CSS)
  • the Examples support the combinations of the invention being synergistic. Synergy is not an expected result when combining antimicrobial agents and certainly not when combining four antimicrobial agents and/or against bacteria which is multi drug resistant such as ESBL strains.
  • the Examples support the combinations of the invention being synergistic against drug-resistant bacteria and hence providing a solution to the worldwide problem of antimicrobial resistance as discussed hereinabove. This is a significant advance in the art.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une combinaison comprenant au moins quatre agents antimicrobiens choisis parmi la rifampicine, la lévofloxacine, la polymyxine E, la polymyxine B, la doxycycline, la ceftazidime, et leurs dérivés pharmaceutiquement acceptables. L'invention concerne également la combinaison destinée à être utilisée dans le traitement d'une infection bactérienne.
PCT/GB2023/052429 2022-09-20 2023-09-20 Combinaisons antimicrobiennes WO2024062236A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2213750.9A GB202213750D0 (en) 2022-09-20 2022-09-20 Antimicrobial
GB2213750.9 2022-09-20

Publications (1)

Publication Number Publication Date
WO2024062236A1 true WO2024062236A1 (fr) 2024-03-28

Family

ID=84817834

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2023/052429 WO2024062236A1 (fr) 2022-09-20 2023-09-20 Combinaisons antimicrobiennes

Country Status (2)

Country Link
GB (1) GB202213750D0 (fr)
WO (1) WO2024062236A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028074A1 (fr) 1998-11-09 2000-05-18 St. George's Enterprises Limited Procede de criblage d'agents antibacteriens
WO2005014585A1 (fr) 2003-08-08 2005-02-17 Ulysses Pharmaceutical Products Inc. Quinazolinyl nitrofuranes halogenes utilises comme agents antibacteriens
WO2015114340A1 (fr) 2014-01-30 2015-08-06 Helperby Therapeutics Limited Thérapies combinatoires par zidovudine pour le traitement d'infections microbiennes
WO2018011562A1 (fr) 2016-07-12 2018-01-18 Helperby Therapeutics Limited Combinaison comprenant de la zidovudine et un carbapenem

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028074A1 (fr) 1998-11-09 2000-05-18 St. George's Enterprises Limited Procede de criblage d'agents antibacteriens
WO2005014585A1 (fr) 2003-08-08 2005-02-17 Ulysses Pharmaceutical Products Inc. Quinazolinyl nitrofuranes halogenes utilises comme agents antibacteriens
WO2015114340A1 (fr) 2014-01-30 2015-08-06 Helperby Therapeutics Limited Thérapies combinatoires par zidovudine pour le traitement d'infections microbiennes
WO2018011562A1 (fr) 2016-07-12 2018-01-18 Helperby Therapeutics Limited Combinaison comprenant de la zidovudine et un carbapenem

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Nature Reviews", DRUG DISCOVERY, vol. 1, 2002, pages 895 - 910
"Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS AND WILKINS
BALAJI V ET AL: "Polymyxins: Antimicrobial susceptibility concerns and therapeutic options", INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, MEDKNOW PUBLICATIONS AND MEDIA PVT. LTD, IN, vol. 29, no. 3, 30 June 2011 (2011-06-30), pages 230 - 242, XP009500107, ISSN: 1998-3646, DOI: 10.4103/0255-0857.83905 *
BERGE ET AL., J PHARM SCI, vol. 66, 1977, pages 1 - 19
LOZNIEWSKI A ET AL: "Infections osteo-articulaires a Enterobacter spp. au CHU de Nancy (1990-1994)", MEDECINE ET MALADIES INFECTIEUSES, SOCIETE FRANCAISE D'EDITIONS MEDICALES, PARIS, FR, vol. 27, no. 10, 1 October 1997 (1997-10-01), pages 856 - 861, XP004925021, ISSN: 0399-077X, DOI: 10.1016/S0399-077X(97)80059-5 *
NATURE REVIEWS, DRUG DISCOVERY, vol. 1, 2002, pages 895 - 910
ORHAN ET AL., J. CLIN. MICROBIOL., vol. 43, no. 1, 2005, pages 140
THE REVIEW ON ANTIMICROBIAL RESISTANCE, May 2016 (2016-05-01)
THEA BRENNAN-KROHN ET AL: "Synergistic Activity of Colistin-Containing Combinations against Colistin-Resistant Enterobacteriaceae", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1 October 2018 (2018-10-01), United States, XP055729587, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153801/pdf/e00873-18.pdf> DOI: 10.1128/AAC.00873-18 *

Also Published As

Publication number Publication date
GB202213750D0 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
US9757427B2 (en) Combination comprising zidovudine and polymyxin
CA3030532C (fr) Combinaison comprenant de la zidovudine et un carbapenem
EP3233105B1 (fr) Nouvelle combinaison et utilisation associée
CA2936714A1 (fr) Combinaisons comprenant de la zidovudine, une polymyxine et un antibiotique antituberculeux et leurs utilisations
JP2024009968A (ja) ジドブジン及び抗微生物化合物を含む組み合わせ
US20190328832A1 (en) Antimicrobial combinations
WO2018172733A1 (fr) Combinaisons de polymyxines
WO2024062236A1 (fr) Combinaisons antimicrobiennes
WO2024062235A1 (fr) Associations antimicrobiennes
US20240197767A1 (en) Combination of zidovudine with a tetracycline antibiotic
US20230233559A1 (en) Combination of zidovudine and fluoroquinolone antibiotic
WO2017220982A1 (fr) Combinaison comprenant de la pipérine et des polymyxines pour le traitement d&#39;infections microbiennes
US20200000742A1 (en) Combination

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23782572

Country of ref document: EP

Kind code of ref document: A1